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Preventive Care
Controversies, Challenges and 
Upcoming Changes in Guidelines
Randa Sifri, MD
Objectives
u Organizations who make guidelines
u Current guidelines for average-risk adults, with a 
focus on guidelines with differing 
recommendations and challenges to 
implementation/operational issues
u Preview of upcoming changes in guidelines
u Cases to illustrate some of the common questions 
that come up in delivering office-based 




u US Preventive Services Task Force
u Considered the most “conservative” and 
evidence-based guidelines
u Pt Protection and Affordable Care Act covers 
preventive services graded “A” or “B”
u Disease-focused organizations (ACS, 
ADA, NCEP, etc.)
u Centers for Disease Control (CDC)
u Medical subspecialty organizations 
(AAFP, ACOG, AAP, ACP, etc.)
US Preventive Services Task 
Force
u Created in 1984, First edition, 1989—guidelines now released in journals 
and on their website
u Independent organization, convened by the AHRQ: 16 Experts from Family 
Medicine, Pediatrics, Internal Medicine, OB/GYN, Geriatrics, Preventive 
Medicine, Public Health, Behavioral Medicine, and Nursing
u Supported by outside experts
u Evidence-based guidelines (graded recommendations)
u Does NOT incorporate cost-effectiveness 
u App: Prevention TaskForce
https://www.uspreventiveservicestaskforce.org/apps/
USPSTF RECOMMENDATIONS AND RATINGS
A. The USPSTF strongly recommends that clinicians routinely provide 
(the service) to eligible patients
B. The USPSTF recommends that clinicians routinely provide (the 
service) to eligible patients
C. The USPSTF makes no recommendation for or against routine 
provision of (the service)
D. The USPSTF recommends against routinely providing (the service) to 
asymptomatic patients
I. The USPSTF concludes that the evidence is insufficient to 
recommend for or against routinely providing (the service)
Breast Cancer Screening
(2016)
u The USPSTF recommends against routine screening 
mammography in women 40-49 years old.  Decision should 
be individualized – “C”
u Biennial screening mammography for women 50-74 years 
old – “B”
u Women > 75 years old – “I”
u Dense Breasts, other imaging – “I”
New Guideline in Process
u Currently in Draft Research Plan stage
(Draft Research Plan->Final research plan->Draft 








u Ages 40-44:  Should have the choice to start annual 
breast cancer screening with mammograms if they 
wish to do so
u Ages 45-54:  Annual mammograms
u Ages 55 and older:  Mammograms every 2 years or 
can continue yearly screening
u Screening should continue as long as a woman is in 
good health and is expected to have at least 10 years 
of life expectancy
u Clinical breast examination is not recommended
Controversies and Challenges
u Somewhat confusing guidelines 
u Stick to guidelines you feel most comfortable/agree 
with 
u When do you start talking to your patients about 
starting mammograms?
u When do you start talking to your patients about 
stopping mammograms?
u Recognize that Jefferson Breast Imaging Center recalls 
all mammogram patients yearly, regardless of age
u Medical Assistants will often pre-order annual 




u The USPSTF recommends screening for CRC at 
ages 50-75 years old – “A”
u gFOBT/FIT annual
u sDNA-FIT every 3 years
u Cx every 10 years
u CT colonography every 5 years
u Flex Sig every 5 years
u Flex Sig with FIT:  FS every 10 years plus FIT every year
u Decision to screen patient 76-85 years old 
should be individualized – “C”
u Recommends against screening in ages >85 
years old – “D”
New Guideline in Progress 
u Draft Recommendation Stage (10/2020):
u 50-75 yo:  “A”
u 45-49 yo:  “B”  (New)
u 76-85 yo:  “C”
Age to start
u US Multi-Society Task Force recommends starting at 45 
yo in Black adults (weak recommendation) 
u ACS issued a “qualified” recommendation to begin 
screening at age 45 yo in all adults; starting at 50 yo is a 
“strong” recommendation
u Recommends that clinicians discourage individuals >85yo 
from continuing CRC screening (“qualified”)
u AAFP does not address screening before age 50 yo
ACS (2018)
Recommends screening with either a high-sensitivity stool-based test or a structural 
exam, depending on patient preference and test availability
Structural exams
Flex sig q 5 years
Colonoscopy q 10 years
CT colonography q 5 years
Stool-based tests
Annual high-sensitivity FOBT or FIT 
Stool DNA test with high sensitivity for cancer, every 3 years
JFMA CRC Screening Policy
u Colonoscopy is preferred screening modality, with FIT as alternative
u Direct Access Referral to Colorectal Surgery
(3-3941 or 5-5896)
u Direct Access Referral to GI (5-5112)
Controversies and Challenges
u Age of starting, and questions about insurance coverage 
when starting at 45 yo
u Additional problem: insurance issues when patient is found 
to have a polyp on a screening exam (becomes diagnostic, 
and patient may incur a charge)
u Direct access scheduling has been successful
u FIT follow up and documentation has been suboptimal 
at JFMA




u The USPSTF concludes that the decision to undergo PSA-
based screening for prostate cancer should be an 
individual one in men 55-69yo – “C”
u Recommends against screening for prostate cancer in men 
>70 years old – “D”
u No mention of DRE in the guideline
ACS Guidelines (2010)
u Start conversations about screening at age 50yo and 
earlier in African American men and men with FDR of 
prostate cancer before age 65yo
u Focus on shared decision making
§ Discuss pros and cons
§ Consider patient preferences
§ Individualize the decision
u If patient wants provider to make decision, patient’s 
values and beliefs should be taken into consideration
u Annual PSA with or without DRE, if PSA is >2.5 ng/ml
u If PSA is <2.5 ng/ml, can retest in 2 years
Other recommendations
u AAFP recommends against screening
u ACP recommends discussing benefits and harms with 
men 50-69yo who have a life expectancy greater than 
10-15 years
u American Urological Association recommends SDM with 
men 55-69yo, with a life expectancy more than 10-15 
years
Controversies and Challenges
u How best to do SDM?  Your experience?
u One example:
u A man who chooses to be screened might place a higher 
value on finding cancer early, might be willing to be 
treated without definite expectation of benefit, and might 
be willing to risk injury to urinary, sexual, and/or bowel 
function
u A man who chooses not to be screening might place a 
higher value on avoiding the potential harms of screening 
and treatment, such as anxiety or the risk of injury to 
urinary, sexual, or bowel function
Lung Cancer Screening (2013)
u Adults aged 55-80:
u Screen with annual low-dose CT in adults with a 30 pack-
year smoking hx and currently smoke or have quit within 
the past 15 years – “B”
u Screening should be discontinued once a person has not 
smoked for 15 years or develops a health problem that 
substantially limits life expectancy or the ability or 
willingness to have curative lung surgery
New guideline in progress
u In the draft recommendation stage, no longer taking 
public comments
u LCS recommended in adults ages 50-80 years who have 
a 20 pack-year smoking history and currently smoke or 
have quit within the past 15 years – “B”
Other recommendations
u ACS (2013):  55-74yo, with at least a 30 pack-year 
history
u American College of Chest Physicians/ASCO/American 
Thoracic Society:  55-74yo, 30 pack-year history
Controversies and Challenges
u Identifying eligible patients:
u Determining pack-years takes time
u Jefferson’s Lung Cancer Screening program (direct 
referral):  Will determine eligibility, do SDM, schedule 
the CT, give results, and arrange follow up (whether if 
positive or negative result)
u Screening rates are less than 5-10% nationally
u Research study starting in March at JFMA:  using an 
external health educator-driven process (prior to their 
office visit) to identify and contact eligible patients, 
provide education/SDM around LCS, and make 




u The USPSTF strongly recommends screening for cervical cancer 
in women who have been active and have a cervix  – “A”
u Ages 21-29:  every 3 years
u Ages 30-65:  every 3 years with co-testing or every 5 
years with HPV testing alone or with co-testing
u The USPSTF recommends against routinely screening women 
older than age 65 for cervical cancer if they have had adequate 
recent screening with normal PAP smears and are not otherwise 
at high risk for cervical cancer – “D”
u The USPSTF recommends against routine PAP smear screening in 




u Start at age 25 and undergo primary HPV testing every 5 
years through age 65 (preferred)
u If primary HPV testing is not available, then individuals  
between ages 25-65 years should be screened with 
contesting every 5 years or cytology alone every 3 years
u AAFP:  in agreement with the USPSTF
Controversies and Challenges
u Bimanual exam:  Any role?
u What is “adequate screening” in women over 65 yo?
u What if have a normal screen at 63yo?
Aspirin for Primary Prevention of 
Cardiovascular Events and Colorectal 
Cancer
(2016)
u The USPSTF recommends the use of low dose aspirin for persons 
age 50-59 years who have a 10% or greater 10-year CVD risk, are 
not at increased risk for bleeding, have a life expectancy of at 
least 10 years and are willing to take low-dose aspirin daily for at 
least 10 years– “B”
u The USPSTF recommends that the decision to use low dose aspirin 
for persons age 60-69 years who have a 10% or greater 10-year CVD 
risk should be individualized – “C”
u For adults younger than 50yo or 70yo or older – “I”
u ACC/AHA risk calculator:  http://tools.acc.org/ASCVD-Risk-
Estimator/
u Age, sex, race/ethnicity, TC, HDL, SBP, HTN Tx, DM, 
Smoking
Other recommendations
u AHA/American Stroke Association:  recommend low dose 
ASA in adults whose 10-year CVD risk is 6-10%
u ADA recommends low dose ASA in patients with Type 1 
or Type 2 diabetes with an CVD risk >10%
u AAFP is similar to USPSTF
High Blood Pressure 
Screening
(2015)
u The USPSTF strongly recommends that clinicians 
screen adults aged 18 and older for high blood 
pressure – “A”
u The USPSTF recommends obtaining measurements 
outside of the clinical setting for diagnostic 
confirmation before starting treatment  (ambulatory 
BP monitoring is preferred over home BP monitoring)
u For ages 18-39yo, if normal BP (<130/<85) and no other 
RF, can check every 3-5 years
u For ages 40yo and over, or if overweight/obese or 
African American, should check annually
Other recommendations
u JNC7 (JNC8 in 2014 does not address screening)
u <120/<80 - recheck in two years
u 120–139/80–89 - recheck in one year
u AHA
u At least once every 2 years in adults with BP less than 120/80
u AAFP is similar to USPSTF
Lipid Disorders
USPSTF last addressed in 2013
Since replaced with guidelines for:
Statin Use for the Primary Prevention of 
Cardiovascular Disease in Adults: 
Preventive Medication (2016)
Other recommendations
u National Cholesterol Education Program (NCEP)/American 
Heart Association: 
u A fasting lipoprotein profile (total cholesterol, LDL-C, HDL-C, 
and TG) in all adults over the age of 20 once every 5 years
u The AAFP strongly recommends periodic cholesterol 
measurement in men aged 35 to 65 and in women aged 45 
to 65
u The American College of Obstetricians and Gynecologists 
recommends screening women every 5 years beginning at 
age 45; screening is recommended for women aged 19-44 
based on risk factors.
Statin Use for the Primary 
Prevention of Cardiovascular 
Disease in Adults:  Preventive 
Medication
(2016)
u “B”:  The USPSTF recommends that adults without a 
h/o CVD use a low-to-moderate dose statin for the 
prevention of CVD and mortality when ALL of following 
criteria are met:
u Ages 40-75
u Have 1 or more CVD RF (dyslipidemia, DM, HTN, smoking)
u Have a calculated 10-year risk of CVD of 10% or greater
u If have all the above but CVD risk is 7.5-10%:  “C”
New Guideline in Progress
u Final Research Plan stage (no longer taking public 
comment)
u USPSTF does recommend measurement of Total 
Cholesterol, LDL and HDL in persons at 40-75yo.  The 
optimal interval is uncertain but every 5 years is 
thought to be appropriate
Other recommendations
u ACC/AHA:  recommend statins in asymptomatic adults, 
40-75yo, without a h/o CVD who have an LCL of 70-189 
mg/dl if they also have DM or an estimated 10-year CVD 
risk of 7.5% or greater (fixed dose statin therapy)
Abnormal Blood Glucose and 
Type II Diabetes Mellitus
(2015)
Ages 40-70:  USPSTF recommends screening for 
abnormal blood glucose for persons who are overweight 
or obese.  Clinicians should offer or refer patients with 
abnormal blood glucose to intensive behavioral 
counseling interventions to promote a healthful diet and 
physical activity – “B”
– A1c, FPG, oral GTT all acceptable
– Rescreening every 3 years may be reasonable (evidence 
limited)
Consider screening in persons with one or more Risk 
Factors:  family h/o DM, h/o gestational DM, member of 
certain racial/ethnic groups 
New guideline in progress
u In Final Research Plan stage
Other recommendations
u ADA:  Screen adults ages 45 years or older and 
screen in persons with multiple risk factors 
regardless of age
u AAFP/American Association of Clinical 
Endocrinologists:  recommend screening in 
persons with risk factors only
Controversies and Challenges
u What is intensive behavioral counseling?
“Behavioral interventions that have an effect on CVD risk 
and delay or avoid progression of glucose abnormalities to 
DM combine counseling on a healthful diet and physical 
activity and are intensive, with multiple contacts over 
extended periods”
“The evidence is insufficient to conclude that 
pharmacologic interventions have the same multifactorial 
benefits as behavioral interventions”
Interventions for Tobacco Smoking 
Cessation in Adults
(2021)
u The USPSTF recommends asking all adults about 
tobacco use, advise them to stop using tobacco, and 
provide behavioral interventions and FDA-approved 
pharmacotherapy for cessation to nonpregnant adults 
who use tobacco - “A”
u Assessment:  5 A’s (ask, advise, assess willingness to 
quit, assist, arrange f/u) or Ask, advise, refer
u Interventions:  Best for combo behavioral counseling 
and pharmacotherapy but either alone have benefits
Other recommendations
u AAFP, ACP, ACOG all have a similar recommendation
u USPSTF states that the current evidence is insufficient 
to assess the balance of benefits and harms of e-
cigarettes for tobacco cessation – “I”
u Other organizations are varied as to whether they 
recommend screening for e-cigarette use or whether to 
use e-cigarettes as a smoking cessation method
Chlamydial and Gonorrhea Infection
(2014)
u The USPSTF strongly recommends that 
clinicians routinely screen all sexually 
active women aged 24 years and 
younger, and in older women at 
increased risk for infection– “B”
u Interval not addressed, based on sexual 
history/risk
u The USPSTF concludes that the 
evidence is insufficient to recommend 
for or against routinely screening 
asymptomatic – “I”
New guideline in progress 




u Annual screening for chlamydia and gonorrhea in all 
sexually active females, aged 25yo or younger and in older 
women with RF (new or multiple sex partners and those 
reporting that their sex partner may have a concurrent sex 
partner)
u AAFP:  same as the USPSTF
u ACOG:  screening for chlamydia and gonorrhea in 
sexually active females aged 25yo and younger
Osteoporosis Screening
(2018)
u The USPSTF recommends screening for women aged 
65 and older and in younger women who are at 
increased risk of osteoporosis, as determined by a 
formal clinical risk assessment– “B”
u Several tools acceptable:  FRAX tool, Osteoporosis Risk Assessment 
Instrument (ORAI), others
u Unclear interval
u Insufficient evidence to assess balance of benefits 
and harms of screening in men – “I”
Other recommendations
u National Osteoporosis Foundation (2014):  recommends 
screening in all women 65yo and older and all men 70yo 
and older; screening in postmenopausal women youger 
than 65yo and men, 50-69yo based on RF profile
u AAFP:  Similar to USPSTF
Additional “A” or “B” 
Recommendations
u All women planning or capable of pregnancy take 400 – 800 µg of folic acid 
daily (2017) – “A”
u Screen for depression in adults (2016) – “B”
u One time screening for AAA by ultrasound in men aged 65-75 who have ever 
smoked (2019) – “B”
u BRCA counseling and testing for women at increased risk (2019) – “B”
u Screening and Behavioral counseling intervention to reduce alcohol misuse by 
adults (2018) – “B”
u Breast Cancer Medication use to reduce risk:  women at 
increased risk for breast cancer, ages 35yo and older (2019) –
“B”
u Screen adults 18yo and older for unhealthy drug use (2018) –
“B”
u Syphilis testing for high risk adults (2016) – “A”
u Offer or refer adults with a BMI of 30 or higher to intensive, 
multicomponent behavioral interventions (2018) – “B”
u Falls Prevention in Community-Dwelling Older Adults 65yo and 
older (2018) – “B”
u Offer or refer adults with CVD disease RF to behavioral 
counseling interventions to promote a healthy diet and 
physical activity (2020) – “B”
u Screen for Hep B in adults at increased risk for infection 
(2020) – “B”
u Screen for Hep C in adults ages 18-79yo (2020) – “B”
u Screen for HIV in adults 15-65yo (2019) – “A”
u Screen for intimate partner violence in women of 
reproductive age and refer screen+ women for support 
services (2018) – “B”
u Screen for latent TB in populations at increased risk (2016) –
“B”
u Offer PrEP to persons at high risk of HIV acquisition (2019) –
“A”
Getting Preventive Care Done
• Physician recommendation is KEY, but team-based care is 
critical in optimal delivery
• JFMA strategies
• Epic/BPAs, Epic/MyChart
• Office Policy, including MA involvement




Health Maintenance Exams vs. 
Opportunistic Preventive Care
u Evidence/Research is almost always directed at 
individual services, less available around scheduling 
regular health maintenance exams (HME)
u Some data that cancer screening rates are higher if a 
patient gets regular HME
Case #1
u 83yo female, asking if she should continue getting 
breast cancer screening
u BMI of 28, generally in “good” health, nonsmoker
u Mobile without difficulty, one hospitalization in last 12 
months, able to do own ADLs and IADLs, lives 
independently
u +DM
u No lung disease, h/o cancer, CHF 
How do you decide?
Calculating life expectancy:
example of risk calculator
u Lee Schonberg Index
u https://eprognosis.ucsf.edu/leeschonberg-result.php
u Includes risk of 5-year, 10-year and 14-year mortality as 
well as life expectancy
u Includes physician’s assessment of patient’s 10-year 
mortality rate
u This patient has a life expectancy of 12.6-14.3 years
Case #2
u 28 year old male, comes in for an office visit and states 
he wants a full physical and his “annual labs”
u Has no chronic diseases, just wants a “check up”
How do you approach the visit?
u History-taking and counseling of most evidence-based 
benefit for this patient
u PMH, FH 
u SH: Sexual history, Tobacco/Drug/ETOH history 
u Depression screening
u Physical Exam
u Ht: 5’10”, Wt: 202 (BMI of 29), Blood pressure 118/76
u Counsel on diet/exercise
u Little guidance from the evidence of extent of PE
u Laboratory tests/Vaccines
u Lipids? A1c? Hep B or C? HIV? Syphilis?  Chlamydia/GC?
